药物代谢基因多态性作为一线抗结核药物性肝损伤的危险因素
Polymorphisms in drug metabolism genes as a risk factor for first-line anti-tuberculosis drug-induced liver injury.
作者信息
Meitei Heikrujam Nilkanta, Pandey Anupama, Haobam Reena
机构信息
Department of Biotechnology, Manipur University, Canchipur, Imphal, Manipur, 795003, India.
出版信息
Mol Biol Rep. 2023 Mar;50(3):2893-2900. doi: 10.1007/s11033-022-08158-7. Epub 2022 Dec 23.
BACKGROUND
Anti-tuberculosis drug-induced liver injury (AT-DILI) is one of the most common side effects in TB patients during treatment. The prime cause of liver injury during TB treatment is reported to be isoniazid and its metabolites. Different factors influenced the development of AT-DILI, and genetic factors are one of the major factors.
METHODS AND RESULTS
Polymorphisms in drug metabolism genes like NAT2, CYP2E1, PXR, and GST have been reported to be associated with AT-DILI, and they are one of the major areas of focus at present. Attempts are met in this review to analyse the different markers in these drug metabolism genes for their association with AT-DILI.
CONCLUSION
A better understanding of the polymorphisms in these genes and their functional effects will give better insights into the development of AT-DILI, and it could facilitate in designing and developing more effective personalized treatment for TB.
背景
抗结核药物性肝损伤（AT - DILI）是结核病患者治疗期间最常见的副作用之一。据报道，结核病治疗期间肝损伤的主要原因是异烟肼及其代谢产物。不同因素影响了AT - DILI的发生发展，遗传因素是主要因素之一。
方法与结果
已报道药物代谢基因如NAT2、CYP2E1、PXR和GST的多态性与AT - DILI相关，它们是目前主要的研究重点领域之一。本综述试图分析这些药物代谢基因中的不同标志物与AT - DILI的关联。
结论
更好地了解这些基因的多态性及其功能效应将有助于深入了解AT - DILI的发生发展，并有助于设计和开发更有效的结核病个性化治疗方案。
Zotero 插件